Multiple drugs for treating auto-immune disease are focused on primarily blocking IFN-I or TNFα (e.g., with Janus kinase inhibitors (JAKi) and anti-TNFα antibodies), which might lead to undesired up-/dysregulation of the untargeted one (30). The gene discussed is TNF; the disease is immune system disorder.